Wartość Przewidiwany EPS Q/Q organizacji Acceleron Pharma Inc to -2.11%
Perspektywiczna kwartalna stopa wzrostu z roka (Estimated quarterly EPS growth rate) rok do roku, to szacowany wzrost wartości EPS spółki na następny kwartał w porównaniu do wyników z poprzedniego kwartału.
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.